Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Qilian International Holding Group Limited (BGM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: BGM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -66.18% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.48B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.46 | 52 Weeks Range 3.33 - 17.17 | Updated Date 06/16/2025 |
52 Weeks Range 3.33 - 17.17 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -26.32% | Operating Margin (TTM) -5.41% |
Management Effectiveness
Return on Assets (TTM) -3.84% | Return on Equity (TTM) -16.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2465318227 | Price to Sales(TTM) 83.14 |
Enterprise Value 2465318227 | Price to Sales(TTM) 83.14 | ||
Enterprise Value to Revenue 98.23 | Enterprise Value to EBITDA 2801.9 | Shares Outstanding 163960000 | Shares Floating 2832616 |
Shares Outstanding 163960000 | Shares Floating 2832616 | ||
Percent Insiders 7.29 | Percent Institutions - |
Upturn AI SWOT
Qilian International Holding Group Limited
Company Overview
History and Background
Qilian International Holding Group Limited is a company operating in China. The specifics of its founding year, significant milestones, and evolution are not readily available in current public data. This makes providing a detailed historical account challenging.
Core Business Areas
- Pharmaceutical Products: Production and distribution of various pharmaceutical products, including traditional Chinese medicine and chemical drugs.
- Nutraceutical Products: Development and sale of nutraceutical products, often derived from natural sources and marketed for health benefits.
- Medical Devices: Manufacture and sale of various medical devices, although specifics are not available.
Leadership and Structure
Details regarding Qilian International Holding Group Limited's specific leadership team and organizational structure are not readily available in current public data.
Top Products and Market Share
Key Offerings
- Pharmaceuticals: Various pharmaceutical products (exact product details are not available), with market share data not publicly disclosed. Competitors: Other Chinese pharmaceutical companies.
- Nutraceuticals: Nutraceutical products (exact product details are not available), with market share data not publicly disclosed. Competitors: Other Chinese nutraceutical companies.
- Medical Devices: Details regarding their medical device offerings and market share are not available. Competitors: Other Chinese medical device companies.
Market Dynamics
Industry Overview
The Chinese pharmaceutical, nutraceutical, and medical device industries are experiencing growth, driven by an aging population, increasing healthcare spending, and government initiatives to improve healthcare access. However, these industries are also highly competitive and subject to regulatory scrutiny.
Positioning
Qilian International Holding Group Limited's position within these industries is unclear due to limited publicly available information. Their competitive advantages are not apparent without more data.
Total Addressable Market (TAM)
The TAM for China's pharmaceutical, nutraceutical, and medical device markets is substantial, estimated to be in the hundreds of billions of dollars. Qilian's positioning with respect to this TAM is unknown due to a lack of publicly available market share information.
Upturn SWOT Analysis
Strengths
- Established operations in China
- Potential for growth in the Chinese market
- Diversified product portfolio (pharmaceuticals, nutraceuticals, medical devices)
Weaknesses
- Limited financial transparency
- Lack of publicly available market share data
- Uncertainty about regulatory compliance
- Reliance on the Chinese market
Opportunities
- Expanding into new product lines
- Increasing market share in existing product lines
- Leveraging government support for healthcare development
- Entering new geographic markets
Threats
- Intense competition from domestic and international players
- Stringent regulatory requirements
- Price pressures
- Economic slowdown in China
Competitors and Market Share
Key Competitors
Competitive Landscape
A comprehensive competitive landscape evaluation cannot be conducted due to a lack of available data on market share and competitor activities.
Growth Trajectory and Initiatives
Historical Growth: Assessment of historical growth trends is not possible due to the unavailability of reliable financial data.
Future Projections: Future growth projections cannot be provided accurately without sufficient financial data and analyst estimates.
Recent Initiatives: Recent strategic initiatives are not publicly available.
Summary
Qilian International Holding Group Limited operates in the Chinese pharmaceutical, nutraceutical, and medical device industries. However, a lack of publicly available information, particularly regarding financial performance and market share, makes it challenging to assess the company's strength and future prospects. The company faces potential risks and opportunities inherent in these competitive and regulated industries. More information is needed to make an informed investment decision.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available news articles
- Company press releases (limited)
- Third-party financial databases (limited information)
Disclaimers:
The information provided is based on limited publicly available data and may not be comprehensive or entirely accurate. The analysis is subject to uncertainty due to data limitations. This is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Qilian International Holding Group Limited
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-08-12 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 298 | Website https://www.bgm.ltd |
Full time employees 298 | Website https://www.bgm.ltd | ||
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.